JPWO2021046442A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021046442A5 JPWO2021046442A5 JP2022514704A JP2022514704A JPWO2021046442A5 JP WO2021046442 A5 JPWO2021046442 A5 JP WO2021046442A5 JP 2022514704 A JP2022514704 A JP 2022514704A JP 2022514704 A JP2022514704 A JP 2022514704A JP WO2021046442 A5 JPWO2021046442 A5 JP WO2021046442A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- seq
- crispr
- target nucleic
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000007523 nucleic acids Chemical class 0.000 claims description 129
- 108020004707 nucleic acids Proteins 0.000 claims description 118
- 102000039446 nucleic acids Human genes 0.000 claims description 118
- 229910052720 vanadium Inorganic materials 0.000 claims description 83
- 238000000034 method Methods 0.000 claims description 70
- 108090000623 proteins and genes Proteins 0.000 claims description 58
- 108091033409 CRISPR Proteins 0.000 claims description 57
- 238000010354 CRISPR gene editing Methods 0.000 claims description 57
- 235000018102 proteins Nutrition 0.000 claims description 56
- 102000004169 proteins and genes Human genes 0.000 claims description 56
- 229910052717 sulfur Inorganic materials 0.000 claims description 47
- 229910052700 potassium Inorganic materials 0.000 claims description 44
- 229910052799 carbon Inorganic materials 0.000 claims description 39
- 210000004027 cell Anatomy 0.000 claims description 39
- 229910052757 nitrogen Inorganic materials 0.000 claims description 39
- 239000002773 nucleotide Substances 0.000 claims description 32
- 125000003729 nucleotide group Chemical group 0.000 claims description 32
- 229910052698 phosphorus Inorganic materials 0.000 claims description 32
- 229910052731 fluorine Inorganic materials 0.000 claims description 31
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 30
- 125000006850 spacer group Chemical group 0.000 claims description 29
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 27
- 230000004048 modification Effects 0.000 claims description 27
- 238000012986 modification Methods 0.000 claims description 27
- 229910052727 yttrium Inorganic materials 0.000 claims description 27
- 108010040467 CRISPR-Associated Proteins Proteins 0.000 claims description 19
- 229910052739 hydrogen Inorganic materials 0.000 claims description 19
- 150000001413 amino acids Chemical group 0.000 claims description 14
- 230000008685 targeting Effects 0.000 claims description 9
- 210000005260 human cell Anatomy 0.000 claims description 8
- 210000004962 mammalian cell Anatomy 0.000 claims description 8
- 108020004414 DNA Proteins 0.000 claims description 7
- 238000003780 insertion Methods 0.000 claims description 7
- 230000037431 insertion Effects 0.000 claims description 7
- 102000053602 DNA Human genes 0.000 claims description 6
- 238000003776 cleavage reaction Methods 0.000 claims description 6
- 238000012217 deletion Methods 0.000 claims description 6
- 230000037430 deletion Effects 0.000 claims description 6
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 6
- 230000007017 scission Effects 0.000 claims description 6
- 108091079001 CRISPR RNA Proteins 0.000 claims description 5
- 230000030833 cell death Effects 0.000 claims description 4
- 230000000295 complement effect Effects 0.000 claims description 4
- 230000005782 double-strand break Effects 0.000 claims description 4
- 210000001236 prokaryotic cell Anatomy 0.000 claims description 4
- 238000001890 transfection Methods 0.000 claims description 4
- 230000000593 degrading effect Effects 0.000 claims description 3
- 108010077544 Chromatin Proteins 0.000 claims description 2
- 230000007067 DNA methylation Effects 0.000 claims description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 2
- 208000009889 Herpes Simplex Diseases 0.000 claims description 2
- 108010033040 Histones Proteins 0.000 claims description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 2
- 235000003704 aspartic acid Nutrition 0.000 claims description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 2
- 230000003197 catalytic effect Effects 0.000 claims description 2
- 210000003483 chromatin Anatomy 0.000 claims description 2
- 230000005059 dormancy Effects 0.000 claims description 2
- 210000001808 exosome Anatomy 0.000 claims description 2
- 102000034287 fluorescent proteins Human genes 0.000 claims description 2
- 108091006047 fluorescent proteins Proteins 0.000 claims description 2
- 235000013922 glutamic acid Nutrition 0.000 claims description 2
- 239000004220 glutamic acid Substances 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 239000002502 liposome Substances 0.000 claims description 2
- 230000004807 localization Effects 0.000 claims description 2
- 239000003607 modifier Substances 0.000 claims description 2
- 239000002105 nanoparticle Substances 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 230000001177 retroviral effect Effects 0.000 claims description 2
- 238000013518 transcription Methods 0.000 claims description 2
- 230000035897 transcription Effects 0.000 claims description 2
- 230000002103 transcriptional effect Effects 0.000 claims description 2
- 238000003146 transient transfection Methods 0.000 claims description 2
- 238000012800 visualization Methods 0.000 claims description 2
- 108020004705 Codon Proteins 0.000 claims 1
- 108091028113 Trans-activating crRNA Proteins 0.000 description 5
- 101710163270 Nuclease Proteins 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- -1 A CRISPR-Cas system Chemical class 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962896308P | 2019-09-05 | 2019-09-05 | |
| US62/896,308 | 2019-09-05 | ||
| PCT/US2020/049534 WO2021046442A1 (en) | 2019-09-05 | 2020-09-04 | Novel crispr dna targeting enzymes and systems |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022546594A JP2022546594A (ja) | 2022-11-04 |
| JP2022546594A5 JP2022546594A5 (https=) | 2023-09-11 |
| JPWO2021046442A5 true JPWO2021046442A5 (https=) | 2023-09-11 |
Family
ID=74852250
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022514704A Pending JP2022546594A (ja) | 2019-09-05 | 2020-09-04 | 新規ｃｒｉｓｐｒ ｄｎａターゲティング酵素及びシステム |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20220282283A1 (https=) |
| EP (1) | EP4025588A4 (https=) |
| JP (1) | JP2022546594A (https=) |
| CN (1) | CN114341166A (https=) |
| AU (1) | AU2020341711A1 (https=) |
| CA (1) | CA3153005A1 (https=) |
| WO (1) | WO2021046442A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL308806A (en) | 2021-06-01 | 2024-01-01 | Arbor Biotechnologies Inc | Gene editing systems including nuclease crisper and their uses |
| US12131057B2 (en) * | 2022-01-28 | 2024-10-29 | Western Digital Technologies, Inc. | Encoding and integrity markers for molecular storage applications |
| CN119546757A (zh) | 2022-05-25 | 2025-02-28 | 宏基因组学公司 | 肝酶表达的补充 |
| WO2024173645A1 (en) | 2023-02-15 | 2024-08-22 | Arbor Biotechnologies, Inc. | Gene editing method for inhibiting aberrant splicing in stathmin 2 (stmn2) transcript |
| WO2024187140A2 (en) * | 2023-03-08 | 2024-09-12 | Metagenomi, Inc. | Class 2, type v crispr systems |
| CN118773168B (zh) * | 2023-11-24 | 2025-07-25 | 华智生物技术有限公司 | CRISPR/Cas效应蛋白HT001及系统与应用 |
| WO2025171210A1 (en) | 2024-02-09 | 2025-08-14 | Arbor Biotechnologies, Inc. | Compositions and methods for gene editing via homology-mediated end joining |
| WO2026015832A2 (en) | 2024-07-12 | 2026-01-15 | Arbor Biotechnologies, Inc. | Reverse transcriptases and gene editing systems comprising such |
| WO2026015829A2 (en) | 2024-07-12 | 2026-01-15 | Arbor Biotechnologies, Inc. | Small reverse transcriptases and gene editing systems comprising such |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4159856A1 (en) * | 2015-06-18 | 2023-04-05 | The Broad Institute, Inc. | Novel crispr enzymes and systems |
| US9790490B2 (en) * | 2015-06-18 | 2017-10-17 | The Broad Institute Inc. | CRISPR enzymes and systems |
| WO2016205759A1 (en) * | 2015-06-18 | 2016-12-22 | The Broad Institute Inc. | Engineering and optimization of systems, methods, enzymes and guide scaffolds of cas9 orthologs and variants for sequence manipulation |
| CN109153980B (zh) * | 2015-10-22 | 2023-04-14 | 布罗德研究所有限公司 | Vi-b型crispr酶和系统 |
| JP7109784B2 (ja) * | 2015-10-23 | 2022-08-01 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 遺伝子編集のための進化したＣａｓ９蛋白質 |
| EP3445358B1 (en) * | 2016-04-19 | 2023-11-15 | Keto Patent Group, Inc. | Administration of dihydroberberine |
| WO2018035388A1 (en) * | 2016-08-17 | 2018-02-22 | The Broad Institute, Inc. | Novel crispr enzymes and systems |
| US11168322B2 (en) * | 2017-06-30 | 2021-11-09 | Arbor Biotechnologies, Inc. | CRISPR RNA targeting enzymes and systems and uses thereof |
| US11713452B2 (en) * | 2017-09-08 | 2023-08-01 | University Of North Texas Health Science Center | Engineered CAS9 variants |
| AU2020291467A1 (en) * | 2019-06-14 | 2021-12-23 | Arbor Biotechnologies, Inc. | Novel crispr DNA targeting enzymes and systems |
-
2020
- 2020-09-04 US US17/634,461 patent/US20220282283A1/en not_active Abandoned
- 2020-09-04 CA CA3153005A patent/CA3153005A1/en active Pending
- 2020-09-04 JP JP2022514704A patent/JP2022546594A/ja active Pending
- 2020-09-04 AU AU2020341711A patent/AU2020341711A1/en not_active Abandoned
- 2020-09-04 EP EP20860548.5A patent/EP4025588A4/en not_active Withdrawn
- 2020-09-04 CN CN202080062332.6A patent/CN114341166A/zh active Pending
- 2020-09-04 WO PCT/US2020/049534 patent/WO2021046442A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025161809A5 (https=) | ||
| CN109072235B (zh) | 通过核递送crispr/cas9追踪并操纵细胞rna | |
| JP7689949B2 (ja) | 操作されたデュアルガイド核酸を有するｃｒｉｓｐｒシステム | |
| JP6712948B2 (ja) | 組成物、及びヌクレオチドリピート障害におけるｃｒｉｓｐｒ−ｃａｓ系の使用方法 | |
| CA3060508C (en) | Crispr hybrid dna/rna polynucleotides and methods of use | |
| JP7449646B2 (ja) | 細胞および組織への遺伝子編集タンパク質および組成物の、ベクターなしでの送達 | |
| JP2021532815A5 (https=) | ||
| JP7641952B2 (ja) | 環状一本鎖ポリヌクレオチドを含む核酸送達ベクター | |
| JP2015503535A5 (https=) | ||
| CN105899657A (zh) | 用于改变基因产物表达的crispr-cas系统和方法、结构信息以及诱导型模块化cas酶 | |
| JPWO2021050534A5 (https=) | ||
| JPWO2021046442A5 (https=) | ||
| CA3220846A1 (en) | Rna-guided cas(omega) nucleases and uses thereof in diagnostics and therapy | |
| WO2024131940A1 (zh) | 融合物及其用途 | |
| CN109207518B (zh) | 用于基因转录激活的药物诱导型CRISPR/Cas9系统 | |
| JP2025524456A (ja) | Ｂ２ｍ発現のエピジェネティック制御のための組成物および方法 | |
| Tolmachov et al. | Methods of Transfection with Messenger RNA Gene Vectors | |
| JPWO2021041569A5 (https=) | ||
| JPWO2020252378A5 (https=) | ||
| JPWO2021007563A5 (https=) | ||
| JP2025526403A (ja) | ゲノム編集のための組成物及び方法 | |
| JPWO2023275601A5 (https=) | ||
| CA3155960C (en) | A nucleic acid delivery vector comprising a circular single stranded polynucleotide | |
| JP2025535776A (ja) | 遺伝子を標的化、編集又は修飾するための組成物及び方法 | |
| JP2025525389A (ja) | Ｃｉｉｔａ発現のエピジェネティック調節のための組成物及び方法 |